Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Eligible healthy donors will be at least 18 years of age.
Healthy donors younger than 18 years of age
* This study will access data and specimens from patients who consented to specimen banks (approximately 3262 patients) There is a waiver of consent for this study regarding patient data banked under the tissue banks. * Healthy donors will be consented prior to sample acquisition (approximately 100 patients)
Cohort
Other
Not listed
Freedom from progression
-Defined as RECIST 1.1 based radiographic or clinical progression, with non-progressors censored at last radiographic follow-up
Event-free survival
-Defined as post-treatment ctDNA detection or RECIST 1.1 based radiographic progression
Disease-specific survival
-Defined as death from cancer
Overall survival
-Defined as death from any cause
Pathologic complete response rate
Click on the lead sponsor to view all of their trials.
Washington University School of Medicine
Lead sponsor
Roche Sequencing Solutions
Collaborator
The Foundation for Barnes-Jewish Hospital
Collaborator
National Center for Advancing Translational Sciences (NCATS)
Collaborator
Radiological Society of North America
Collaborator
Skandalaris
Collaborator
The V Foundation for Cancer Research
Collaborator
National Institute of General Medical Sciences (NIGMS)
Collaborator
